Marpai, Inc. MRAI

Marpai, Inc. expands its relationship with Claritev to help employer clients reduce healthcare costs. Partnership expansion with Claritev enables Marpai to offer enhanced cost reduction services to employers.

Marpai, Inc. reported its second quarter 2026 financial results. Quarterly earnings reports directly affect investor sentiment and can drive significant stock price movement for Marpai.

Marpai, Inc. (MRAI) reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue growth and operational performance. The company continues to focus on expanding its market presence and enhancing its technology offerings. Management expressed optimism about future prospects and strategic initiatives aimed at improving profitability and shareholder value. Revenue growth and operational performance indicate a moderately noticeable influence on the company's financial trajectory.

Marpai, Inc. (MRAI) secures $12 million via private placement led by Mitchell Companies. The capital infusion strengthens financial position and may support operations without fundamentally shifting company trajectory.

Marpai Inc. restructures debt with JGB Capital and AXA, decreasing debt service obligations by $26.4 million until 2027 while boosting near-term liquidity. Major debt service cuts and liquidity gains directly strengthen balance sheet and future cash flow.

Marpai Inc. gains 192,000 new estimated member lives across TPA and MarpaiRx PBM platforms and projects positive cash flow plus EBITDA starting August 2026. 192,000 new members and positive EBITDA forecast from August 2026 indicate substantial operational expansion and improved financial outlook.

Marpai, Inc. (MRAI) reported first quarter 2026 financial results. Quarterly results provide performance metrics that can shift near-term investor views and trading activity for Marpai.

Marpai, Inc. announces significant new business wins across TPA and MarpaiRx, solidifying its forecast for profitability. Significant new business wins in core TPA and MarpaiRx segments solidify profitability forecasts, poised to enhance financial trajectory and market sentiment.

Marpai, Inc. secures major strategic marketing collaboration to accelerate MarpaiRx growth nationwide. Major strategic marketing collaboration accelerates nationwide growth of MarpaiRx, significantly enhancing MRAI's trajectory and market performance.

Marpai secures access to a network serving as a major growth catalyst for MarpaiRx, representing up to 1.5 million covered lives. Access to a network covering up to 1.5 million lives acts as a major growth catalyst for MarpaiRx, significantly expanding market reach and revenue potential.

Marpai, Inc. secures major strategic wins for MarpaiRx, adding over 19,000 lives and accelerating high-growth platform expansion. Adding over 19,000 lives through strategic wins significantly expands MarpaiRx's reach and accelerates platform growth, positively impacting future revenue and market performance.

Marpai, Inc. has appointed Mimi Davis as the new President of MarpaiRx, aiming to enhance strategic growth within the company. Davis brings extensive experience in the pharmacy sector, which is expected to drive innovation and improve operational efficiency in MarpaiRx's offerings. The appointment of a seasoned pharmacy executive is likely to significantly impact Marpai's strategic direction and market positioning.

Marpai, Inc. (MRAI) has announced significant momentum for 2026, highlighting key partnerships that are expected to enhance its market position. The company is focusing on expanding its offerings and improving operational efficiencies through these collaborations. This strategic move aims to bolster Marpai's competitive edge in the healthcare technology sector, positioning it for growth in the coming years. Key partnerships and strategic expansions are likely to significantly impact Marpai's future performance and market positioning.

Marpai, Inc. (MRAI) reported its financial results for the third quarter of 2025, highlighting significant growth in revenue and improvements in operational efficiency. The company attributed its success to strategic initiatives and increased demand for its services. Key metrics showed a positive trend, with a notable rise in customer acquisition and retention rates. Management expressed optimism about future performance and outlined plans for continued innovation and market expansion. Significant growth in revenue and operational efficiency indicates a strong potential for future performance and market positioning.

Marpai, Inc. (MRAI) has been recognized as a top third-party administrator for 2025, highlighting its commitment to innovation and excellence in healthcare management. This recognition positions Marpai favorably within the competitive landscape of healthcare administration, potentially enhancing its reputation and attracting new clients. The acknowledgment reflects the company's strategic initiatives and operational effectiveness in delivering quality services. Recognition as a top third-party administrator is likely to significantly enhance Marpai's market position and investor sentiment.

Marpai, Inc. (MRAI) has launched MARPAIRX, a new pharmacy benefits management platform that emphasizes transparency and cost savings for users. The platform aims to provide clear pricing and enhance the overall experience for both employers and employees. By leveraging advanced technology, Marpai seeks to disrupt traditional pharmacy benefit models, potentially leading to significant savings on prescription medications. The initiative is expected to improve access to affordable healthcare solutions and streamline the pharmacy benefits process. The launch of MARPAIRX represents a significant strategic move that could alter the company's competitive positioning and investor sentiment.

Marpai, Inc. (MRAI) reported its financial results for the first quarter of 2025, highlighting key metrics such as revenue growth and operational performance. The company continues to focus on enhancing its technology and expanding its market presence. Management expressed optimism about future prospects and strategic initiatives aimed at improving profitability and customer engagement. Revenue growth and operational performance indicate a moderately noticeable influence on the company's financial trajectory.

Marpai, Inc. has appointed Dallas Scrip as Chief Operating Officer and President of MarpaiRx, aiming to enhance operational excellence and drive profitable growth. Scrip brings extensive experience in scaling healthcare companies and a process-oriented approach to identifying market needs. CEO Damien Lamendola emphasized that Scrip's expertise aligns with Marpai's vision for sustainable growth in the competitive healthcare landscape. The appointment of a seasoned executive like Dallas Scrip is expected to significantly impact Marpai's operational strategy and growth trajectory.

Marpai, Inc. (MRAI) reported its financial results for Q4 and full year 2024, showing a net revenue of $6.6 million in Q4, a 6% decrease from Q3, and a full-year revenue of $28.2 million, down 24.2% year-over-year. Operating expenses improved by 23.7% to $31.2 million for the year. The company achieved a net loss of $22.1 million for the year, a 23.2% reduction from the previous year. Adjusted EBITDA loss improved to $9.1 million from $20.2 million in 2023. CEO Damien Lamendola highlighted a turnaround in reducing losses and plans for growth, including new product launches in 2025. A conference call is scheduled for March 27, 2025, to discuss these results. Significant improvements in financial performance and strategic plans for new product launches indicate a major shift in the company's trajectory.

Marpai, Inc. (OTCQX: MRAI) will host a conference call and webcast on March 27, 2025, at 8:30 a.m. ET to discuss its operational and financial highlights for 2024. The company will report its fourth quarter and full year 2024 results on March 26, 2025, after market close. Marpai operates as a national Third-Party Administrator (TPA) in the $22 billion market, providing healthcare solutions to self-funded employer health plans. The webcast will be available for streaming, and a replay will be accessible for a limited time after the call. The upcoming financial results presentation may moderately influence investor sentiment and provide insights into the company's performance.

Marpai, Inc. has announced a strategic collaboration with Empara to launch a unified Health Engagement Platform aimed at transforming self-funded employer health plans. This platform consolidates various tools into a streamlined experience, providing plan members and administrators with better access to benefits and cost control. Marpai expects to have the full platform operational by the end of Q2 2025, enhancing operational efficiency and member engagement. The collaboration with Empara represents a significant strategic move that could enhance Marpai's competitive position and operational efficiency in the TPA market.

Marpai, Inc. secures up to $5 million in non-dilutive growth funding from JGB. The significant funding injection is expected to have a major impact on Marpai's future growth and market performance.

Marpai, Inc. announced pricing of $700,000 private placement for 621,194 shares of Common Stock at $1.13 per share. Private placement offering may moderately influence financial performance and competitive positioning.

Marpai, Inc. (MRAI) reports third quarter 2024 financial results. The financial results may moderately influence the company's performance and competitive positioning.

Marpai, Inc. will host a webcast on November 12, 2024, to discuss its third quarter 2024 financial results. The webcast discussing third quarter financial results may moderately influence market sentiment and financial performance.

Marpai, Inc. announces new client contract in the southeast with nearly 1,500 employee lives. The new client contract is expected to moderately influence Marpai's financial performance and competitive positioning.

Marpai, Inc. reported financial results for the second quarter of 2024, showing a decrease in net revenues and an increase in operating expenses and losses compared to the same period in 2023. The financial results may moderately influence key areas such as financial performance and competitive positioning.

Marpai, Inc. will host a webcast on August 8, 2024, to discuss its second quarter 2024 financial results. The webcast discussing second quarter financial results is likely to have a significant impact on Marpai, Inc.'s future performance and market sentiment.

Marpai President John Powers selected to speak at three elite healthcare conferences. Selection to speak at prestigious conferences likely to have a significant impact on Marpai's future and market performance.

Marpai, Inc. transitions to OTCQX Best Market from NASDAQ. Transition to OTCQX may impact financial performance and investor visibility.